Is GlaxoSmithKline plc’s Dividend Safe?

GlaxoSmithKline plc’s (LON: GSK) 5.5% hefty pay-out accounts for 90% of earnings. One Fool questions its sustainability.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has had a bad time of it this year, being charged with bribery in China and losing patent protection on blockbuster drug Advair, which accounted for £5bn worth of sales in 2013. This pressure on earnings has brought the dividend under pressure, with the payout now eating up 90% of earnings. With profits forecast to drop a further 14% in 2015, it is possible the dividend will be funded through the balance sheet at some point in the short term.

However, even with all this bad news surrounding the company, I believe the shares are a firm buy. The news is out in the open, and the shares have fallen on the back of it. GlaxoSmithKline is a quality company trading at on a P/E of 12 and I believe the dividend is unlikely to be cut. Here is why.

Copious Cash

The dividend looks supported by some serious cash flowing through the business, rendering the earnings coverage not so worrying in the short term. The company generated £7,222m cash from operations last year, covering the dividend of £3,789m nearly twice.

This is comforting , but even if cash flow proves to be insufficient, the company has another route to payment.

Short-Term Asset Sales To Steady The Ship

The company intends to float its stake in HIV treatment company ViiV Healthcare. Sir Andrew Witty, CEO, predicted ViiV could be worth more than Marks & Spencers! The sale, which could raise between £10bn and £15bn, looks likely to go through in 2016, so if the company can support the dividend for another year cash from the IPO could pick up the slack.

R&D Excellence

Since 2009, GlaxoSmithKline has blown away all competitors, achieving approval for more New Molecular Entities, or new drugs, than any other pharmaceutical company. Even more promisingly, the company has another 40 NMEs in late stage testing that could become profitable treatments over the next few years.

Furthermore, a robust portfolio of seven respiratory drugs should go some way to replacing the revenue from Advair and also cement Glaxo’s leading position in the area.

More Than Just A Dividend Play

If you are buying GlaxoSmithKline purely for the yield, and not the longer-term recovery and rerating, I would pause for thought. There is no guarantee the dividend will continue to be paid, and while a cut looks very unlikely, Glaxo has more to offer than a fantastic yield.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zach Coffell has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »